Role of Pharmacogenomics in Drug Development – An Industry ...

More documents

Recommendations

Info

Farglitazar Clinical Studies• Farglitazar, PPARγ agonist in Phase III studies in Type2 diabetic patients• 647/1106 (59%) subjects provided informed consentand DNA samples for PGx analysis whilst participatingin clinical studies• 555/647 (86%) were categorised as White• White subjects were allocated to three groups basedon study treatment– Farglitazar monotherapy: 6 studies (n=337)– Farglitazar plus glyburide: 1 study (n=77)– Farglitazar plus insulin: 2 studies (n=141)
Farglitazar oedema AE PGxSCNN1B Genetic LocusP valueGeneLDPattern(r 2 )
Page 1 and 2: Role of Pharmacogenomics inDrug Dev
Page 3 and 4: Variation in medicine response to c
Page 5 and 6: GSK Pharmacogenetic StrategyOngoing
Page 7 and 8: Efficacy PGx: Opportunities• Asso
Page 9 and 10: APOE4 - a susceptibility gene varia
Page 11 and 12: ADAS-Cog Score in APOE ε4-Negative
Page 13 and 14: Rosiglitazone in ADPhase III progre
Page 15 and 16: Abacavir and Hypersensitivity (HSR)
Page 17 and 18: Abacavir HSR Prospective PGx study
Page 19: PPARγ agonist FarglitazarOedema AE
Page 23 and 24: Ethical considerations• PGx is no

Role of Pharmacogenomics in Drug Development – An Industry ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?